Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma, Kaposi 4Neoplasms 4HIV Infections 4Acquired Immunodeficiency Syndrome 4

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × tecogalan × Clear all
NCT00002136 2005-06-24

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002137 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002138 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002342 2005-06-24

A Study of Tecogalan Sodium

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡